These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 2513619)
1. [Protein engineering of Pseudomonas exotoxin and its targeting therapy of cancer]. Kondo T Tanpakushitsu Kakusan Koso; 1989 Oct; 34(13):1793-803. PubMed ID: 2513619 [No Abstract] [Full Text] [Related]
2. Clinical trials with Pseudomonas exotoxin immunotoxins. Pai LH; Pastan I Curr Top Microbiol Immunol; 1998; 234():83-96. PubMed ID: 9670614 [No Abstract] [Full Text] [Related]
3. Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications. Wu T; Zhu J Int Immunopharmacol; 2021 Jul; 96():107759. PubMed ID: 34162138 [TBL] [Abstract][Full Text] [Related]
4. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology]. Chiron MF Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366 [TBL] [Abstract][Full Text] [Related]
5. A magic bullet for cancer--how near and how far? Schnipper LE; Strom TB N Engl J Med; 2001 Jul; 345(4):283-4. PubMed ID: 11474668 [No Abstract] [Full Text] [Related]
6. General strategies in in vivo animal modeling. Vallera DA; Blazar BR Targeted Diagn Ther; 1992; 7():63-77. PubMed ID: 1633310 [No Abstract] [Full Text] [Related]
8. New insights on Morgan RN; Saleh SE; Farrag HA; Aboshanab KM Ther Deliv; 2023 Jan; 14(1):31-60. PubMed ID: 36950853 [TBL] [Abstract][Full Text] [Related]
9. Recombinant antibody fragments and immunotoxin fusions for cancer therapy. Brinkmann U In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057 [TBL] [Abstract][Full Text] [Related]
10. Recombinant toxins for the treatment of cancer. Kreitman RJ Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies for the treatment of cancer: therapeutic strategies. Houghton AN; Larson S Curr Opin Oncol; 1989 Dec; 1(2):258-65. PubMed ID: 2489969 [No Abstract] [Full Text] [Related]
12. Recombinant toxins as novel therapeutic agents. Pastan I; Chaudhary V; FitzGerald DJ Annu Rev Biochem; 1992; 61():331-54. PubMed ID: 1497314 [No Abstract] [Full Text] [Related]
14. Protein engineering strategies. Whitlow M Targeted Diagn Ther; 1992; 7():55-61. PubMed ID: 1633309 [No Abstract] [Full Text] [Related]
15. [CD4-derivatives therapy of HIV carriers]. Mizukami T; Mitsuya H Nihon Rinsho; 1993 Sep; 51 Suppl():327-33. PubMed ID: 8271399 [No Abstract] [Full Text] [Related]
16. Immunoconjugates and immunotoxins for therapy of solid tumors. Hellström I; Trail P; Siegall C; Firestone R; Hellström KE Cancer Chemother Pharmacol; 1996; 38 Suppl():S35-6. PubMed ID: 8765413 [No Abstract] [Full Text] [Related]
17. Vascular targeting--a new approach to the therapy of solid tumors. Burrows FJ; Thorpe PE Pharmacol Ther; 1994 Oct; 64(1):155-74. PubMed ID: 7846113 [TBL] [Abstract][Full Text] [Related]
18. Immunotoxins in the therapy of cancer: from bench to clinic. Ghetie V; Vitetta E Pharmacol Ther; 1994 Sep; 63(3):209-34. PubMed ID: 7831391 [TBL] [Abstract][Full Text] [Related]
19. Immunotoxins: status and prospects. Spooner RA; Lord JM Trends Biotechnol; 1990 Jul; 8(7):189-93. PubMed ID: 1366624 [TBL] [Abstract][Full Text] [Related]
20. Where are the immunotoxins in the clinic? Beijnen JH Pharm World Sci; 1993 Aug; 15(4):145. PubMed ID: 8220296 [No Abstract] [Full Text] [Related] [Next] [New Search]